Akebia Therapeutics, Inc.
AKBA
$1.44
$0.021.06%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 23.93% | 57.01% | 43.13% | 75.84% | -17.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.93% | 57.01% | 43.13% | 75.84% | -17.26% |
| Cost of Revenue | 34.56% | 73.66% | 29.13% | 200.66% | -9.02% |
| Gross Profit | 21.67% | 53.88% | 46.41% | 64.50% | -18.82% |
| SG&A Expenses | -5.73% | 9.72% | -1.34% | 1.20% | 8.80% |
| Depreciation & Amortization | -- | -- | -- | -- | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.50% | 8.78% | -6.92% | -6.90% | 6.30% |
| Operating Income | 40.11% | 135.58% | 272.51% | 195.72% | -441.88% |
| Income Before Tax | 50.73% | 105.76% | 102.88% | 133.98% | -3,814.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 46.31% | 102.69% | 102.88% | 133.98% | -3,814.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.31% | 102.69% | 102.88% | 133.98% | -3,814.01% |
| EBIT | 40.11% | 135.58% | 272.51% | 195.72% | -441.88% |
| EBITDA | -659.55% | 252.25% | 1,124.05% | 384.78% | -106.10% |
| EPS Basic | 55.80% | 102.10% | 102.20% | 129.61% | -3,359.38% |
| Normalized Basic EPS | 61.21% | 104.54% | 103.32% | 132.55% | -837.50% |
| EPS Diluted | 53.80% | 102.00% | 102.20% | 128.89% | -3,468.75% |
| Normalized Diluted EPS | 61.21% | 104.37% | 103.32% | 131.58% | -837.50% |
| Average Basic Shares Outstanding | 21.34% | 25.88% | 25.21% | 14.90% | 15.16% |
| Average Diluted Shares Outstanding | 21.34% | 30.44% | 29.28% | 17.88% | 14.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |